Head-to-Head Comparison of 18FPSMA-1007 and 18FFDG PET/CT in Patients with Triple-Negative Breast Cancer

BACKGROUND: Triple-negative breast cancer (TNBC) exhibits high aggressiveness and a notably poorer prognosis at advanced stages. Nuclear medicine offers new possibilities, not only for diagnosis but also potentially promising therapeutic strategies. This prospective study explores the potential of prostate-specific membrane antigen (PSMA) as a diagnostic and therapeutic target in TNBC. METHODS: F]FDG PET/CT. RESULTS: F]PSMA-1007. CONCLUSIONS: F]PSMA-1007 PET/CT in enhancing both diagnostic and therapeutic approaches for this aggressive breast cancer subtype.